Watch DMAAU. Know when insiders buy.
One email the day a filing lands. Free.
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$137K | $1.7M | −24.5% | — | −$245K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$143K | $2M | +57.1% | — | −$91K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.1M | $213K | — | — | −$125K | — | — | Apr 15 |
| Q3 2025 · Sep 30 | — | — | — | −$264K | $2.2M | — | — | −$56K | — | — | Nov 18 |
| Q2 2025 · Jun 30 | — | — | — | −$132K | $2.3M | — | — | −$107K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$331K | $1.3M | — | — | −$251K | — | — | Aug 14 |
| Q3 2024 · Sep 30 | — | — | — | −$145K | −$145K | — | — | — | — | — | Nov 18 |
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$2.8M | $5.9M | — | — | −$539K | — | — | — | — |
Every number comes from Drugs Made In America Acquisition Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.